Exiqon has signed up a new distribution partner, Link Technologies,
for its locked nucleic acid (LNA) phosphoramidate reagents, used in
genomics research.
A UK Phase I trial has been initiated for XR5944 (also known as
MLN944), a DNA targeting agent under evaluation for the treatment
of advanced cancers. The product is under development by USA-based
firm Millennium Pharmaceuticals and...
Finland's Jurilab has developed a new microarray product designed
for use in DME (drug metabolism enzyme) testing, and also signed up
its first customer for the technology.
The UK biotechnology industry is gearing up for yet another bout of
consolidation with the news that British Biotech has made a £48
million (€73m) offer for Vernalis.
The European Commission has issued its long-awaited response to the
G10 Medicines Report, intended as a blueprint for improving the
European pharmaceutical industry's competitiveness while ensuring
high levels of public health...
Switzerland's Tecan has introduced a range of laboratory automation
workstations, under the Freedom EVO banner, which are designed to
provide fluid handling applications in genomics, proteomics, drug
discovery and clinical diagnostics.
The market for antibacterial drugs is becoming increasingly
unattractive to major pharmaceutical companies, despite continued
strong worldwide demand for these products and the growing threat
of bacterial resistance, according to...
Invitrogen has made a cash offer for fellow US company Molecular
Probes in a deal which would give the firm a very strong presence
in fluorescence reagents for use in labelling molecules for
biological research and drug discovery.
Syrrx has determined the atomic structure of c-Kit kinase, a
receptor-associated tyrosine kinase which has been associated with
a number of malignant cancers.
Argonaut Technologies has introduced a new resin-bound reagent,
MP-TsO-TEMPO that enables medicinal chemists to introduce diversity
into chemical libraries with high purity and yields.
Iceland's deCODE genetics has initiated high-throughput screening
on its Neuregulin 1 pathway targets in schizophrenia in
collaboration with partner Roche.
GlaxoSmithKline has opened an ultra-high-throughput screening
facility at its site in Tres Cantos, Spain, marking a significant
milestone in the company's bid to develop a more industrialised
approach to the process of drug discovery.
Researchers in Germany, Switzerland and the USA have completed a
genome map of the bacteria Helicobacter hepaticus in the
hope of providing new drug targets to treat a related organism that
causes gastrointestinal disease in humans.
While the procedure for designating drugs for orphan diseases has
improved dramatically in the EU, further progress must be made,
says EU biotech group
